Shots:

• I-Mab to receive $180M upfront- $20M on P-I results- and is eligible to receive ~$1.74B which include $840M as development & regulatory milestones while remaining as commercial milestones along with royalties on sales of the therapy outside China
• AbbVie to get an exclusive global license (Ex-greater China) to develop and commercialize lemzoparlimab while I-Mab retains its right in China. Both the companies will conduct clinical trials to evaluate lemzoparlimab in multiple cancers while each partner have the potential to expand the collaboration to additional transformative therapies
• The companies will have the opportunity to further licenses to explore each other's related programs in their respective territories. Lemzoparlimab is an anti-CD47 mAb- designed to minimize inherent binding to normal RBCs while preserving its strong anti-tumor activity

­ Ref: AbbVie | Image:abbvie